Bank of New York Mellon
TARS icon

Bank of New York Mellon’s Tarsus Pharmaceuticals TARS Stock Holding History

Bank of New York Mellon’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.2M Buy
114,458
+7,676
+7% +$490K ﹤0.01% 2212
2026
Q1 		$7.49M Sell
106,782
-978
-0.9% -$68.3K ﹤0.01% 2083
2025
Q4 		$8.82M Sell
107,760
-1,616
-1% -$121K ﹤0.01% 1997
2025
Q3 		$6.5M Buy
109,376
+2,584
+2% +$127K ﹤0.01% 2171
2025
Q2 		$4.33M Buy
106,792
+5,779
+6% +$260K ﹤0.01% 2358
2025
Q1 		$5.19M Sell
101,013
-915
-0.9% -$45.2K ﹤0.01% 2201
2024
Q4 		$5.64M Buy
101,928
+498
+0.5% +$22.6K ﹤0.01% 2229
2024
Q3 		$3.34M Sell
101,430
-21,204
-17% -$596K ﹤0.01% 2502
2024
Q2 		$3.33M Buy
122,634
+26,225
+27% +$882K ﹤0.01% 2535
2024
Q1 		$3.5M Buy
96,409
+14,212
+17% +$418K ﹤0.01% 2490
2023
Q4 		$1.66M Buy
82,197
+10,745
+15% +$179K ﹤0.01% 2922
2023
Q3 		$1.27M Sell
71,452
-179
-0.2% -$3.17K ﹤0.01% 3033
2023
Q2 		$1.29M Buy
71,631
+12,918
+22% +$205K ﹤0.01% 3062
2023
Q1 		$738K Sell
58,713
-538
-0.9% -$7.87K ﹤0.01% 3280
2022
Q4 		$869K Buy
59,251
+5,103
+9% +$84.4K ﹤0.01% 3261
2022
Q3 		$927K Buy
54,148
+9,566
+21% +$152K ﹤0.01% 3248
2022
Q2 		$651K Buy
44,582
+19,471
+78% +$292K ﹤0.01% 3437
2022
Q1 		$423K Sell
25,111
-175
-0.7% -$3.25K ﹤0.01% 3814
2021
Q4 		$569K Buy
25,286
+763
+3% +$19.8K ﹤0.01% 3722
2021
Q3 		$529K Buy
24,523
+2,950
+14% +$73K ﹤0.01% 3779
2021
Q2 		$625K Buy
21,573
+6,099
+39% +$190K ﹤0.01% 3665
2021
Q1 		$499K Sell
15,474
-2,943
-16% -$109K ﹤0.01% 3691
2020
Q4 		$761K Buy
+18,417
New +$525K ﹤0.01% 3408

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bank of New York Mellon's TARS Position: Q2 2026 in Review

Bank of New York Mellon increased its Tarsus Pharmaceuticals (TARS) stake by 7.2% in Q2 2026, buying an estimated $490K and bringing the position to 114,458 shares worth $7.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2212.

Bank of New York Mellon first reported a position in TARS in Q4 2020 and has held it in 23 quarters since. The position peaked at $8.82M in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Bank of New York Mellon held 114,458 shares of Tarsus Pharmaceuticals worth $7.2M as of Q2 2026.
  • Bank of New York Mellon bought 7,676 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $490K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2212 holding.
  • Bank of New York Mellon first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Bank of New York Mellon's Tarsus Pharmaceuticals position peaked at $8.82M in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.